BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 8, 2016
View Archived Issues
Vyriad enters global license agreement with Stinginn
Read More
Eisai reviews accomplishments of first quarter of fiscal 2016
Read More
Merck & Co. patents BACE1 and -2 inhibitors
Read More
Sumitomo Dainippon Pharma discloses Nav1.7 channel blockers
Read More
Millennium Pharmaceuticals describes Nampt inhibitors
Read More
Scripps Research Institute develops MCT1 and/or MCT4 inhibitors
Read More
MyoKardia presents cardiac myosin activators
Read More
MMRF and University of Michigan collaborate on a new molecular profiling initiative
Read More
Autologous BMC is safe and effective in treating patients with atrophic non-unions
Read More
FDA accepts Merck & Co.'s MK-1293 NDA for review
Read More
Mylan completes public offer settlement with Meda
Read More
CheckMate 026 phase III study of Opdivo does not meet primary endpoint
Read More
ZSYM73 affibody in a mouse model of AD
Read More
Shire reports recent developments of second quarter 2016
Read More
UT Southwestern receives funding from NCI to target rising rates of kidney cancer
Read More
Hematogenix announces launch of Ventana PD-L1 (SP142) and (SP263) assays
Read More
FDA approves Merck & Co.'s Keytruda for patients with recurrent or metastatic HNSCC
Read More
Lantern Pharma to evaluate BioNumerik's Tavocept
Read More
FDA grants orphan drug designation to vedolizumab
Read More
Boehringer Ingelheim begins phase II trial of BI-425809 in patients with schizophrenia
Read More
Phase II trial of volixibat in patients with NASH recruiting patients
Read More
Tolerogenic nanoparticles improve biologic drug efficacy
Read More